Stockscreener 앱 받기
9.98
1.84%
0.18
시간 외 거래:
9.97
-0.010
-0.10%
전일 마감가:
$9.80
열려 있는:
$10.1
하루 거래량:
1.54M
Relative Volume:
1.80
시가총액:
$774.35M
수익:
$202.09M
순이익/손실:
$-61.69M
주가수익비율:
-9.2407
EPS:
-1.08
순현금흐름:
$-35.64M
1주 성능:
-16.90%
1개월 성능:
+4.61%
6개월 성능:
-19.77%
1년 성능:
-21.73%
1일 변동 폭
$9.74
$10.16
1주일 범위
$9.74
$12.15
52주 변동 폭
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
EOLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.98 | 774.35M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
161.92 | 70.37B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.19 | 48.41B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
10.71 | 47.91B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.96 | 18.80B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
310.80 | 13.47B | 2.76B | 1.11B | 898.10M | 22.77 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | BTIG Research | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Evolus projects $345M-$355M revenue for 2025 with new product launches - MSN
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its First-Quarter Report - simplywall.st
Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Midday Stock Roundup: Clean Energy Leaps 22% - Orange County Business Journal
Evolus, Inc. Reports Strong Q1 Growth Amid Challenges - TipRanks
EOLS Stock: Needham Reiterates Buy Rating with $22 Target | EOLS Stock News - GuruFocus
Evolus, Inc. (NASDAQ:EOLS) Q1 2025 Earnings Call Transcript - Insider Monkey
What Analysts Are Saying About Evolus Stock - Benzinga
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges - Yahoo
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges By GuruFocus - Investing.com Canada
Evolus, Inc. Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Evolus Q1 2025 results miss forecasts, stock rises - Investing.com Nigeria
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Evolus Inc reports results for the quarter ended March 31Earnings Summary - TradingView
EOLS Q1 Revenue Falls Short but Maintains Strong Momentum for 2025 | EOLS Stock News - GuruFocus
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
Evolus, Inc. SEC 10-Q Report - TradingView
Evolus Inc Q1 2025 Earnings: EPS Misses at -$0.30, Revenue Falls Short at $68.5 Million - GuruFocus
Evolus Reports First Quarter 2025 Results - Yahoo Finance
BioPharma Credit – Partial loan repayment and expanded Evolus facility - QuotedData
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost - GuruFocus
Evolus Secures New $250 Million Credit Facility - TipRanks
Evolus IncEnters New $250 Million Credit Facility With Pharmakon Advisors, Replacing Exisiting $125 Million Credit Agreement - marketscreener.com
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility - Business Wire
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Evolus (EOLS) and Becton Dickinson (BDX) - The Globe and Mail
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven? - simplywall.st
Evolus Inc (EOLS) Shares Gap Down to $11.115 on Apr 28 - GuruFocus
Evolus, Inc. to Host Earnings Call - ACCESS Newswire
Evolus to Report First Quarter Financial Results on May 7, 2025 - BioSpace
Evolus: Two-Product Aesthetics Company With A Competitive Edge (NASDAQ:EOLS) - Seeking Alpha
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus announces commercial launch of Evolysse - MSN
BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - Nasdaq
BTIG Initiates Evolus at Buy With $21 Price Target - marketscreener.com
Evolus initiated with a Buy at BTIG - TipRanks
BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook | EOLS Stock News - GuruFocus
BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook - GuruFocus
Evolus Launches "Drop The F Word" To Redefine Aesthetic Injectables With Evolysse - Nasdaq
Evolus Announces Commercial Launch of Evolysse™ | EOLS Stock New - GuruFocus
Evolus Announces Commercial Launch of Evolysse™ - Yahoo Finance
Evolus Launches “Drop the F Word” Campaign in Advance of the Com - GuruFocus
Game-Changing Cold-X Technology: Evolus Revolutionizes Injectable Aesthetics with Natural Results - Stock Titan
Midday Stock Roundup: Evolus, ICU Medical down - Orange County Business Journal
H.C. Wainwright maintains Buy on Evolus stock with $27 target - Investing.com
H.C. Wainwright maintains Buy on Evolus stock with $27 target By Investing.com - Investing.com Canada
Evolus stock hits 52-week low at $9.22 amid market challenges - Investing.com Canada
Evolus stock hits 52-week low at $9.22 amid market challenges By Investing.com - Investing.com South Africa
Breaking Down Evolus: 8 Analysts Share Their Views - Benzinga
Investors Give Evolus, Inc. (NASDAQ:EOLS) Shares A 31% Hiding - simplywall.st
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.78%
2.72%
자본화:
|
볼륨(24시간):